AMNOG may cause havoc in German diabetes market
Bristol-Myers Squibb/AstraZeneca, Novartis, and Merck & Co could soon have to drop the prices of their dipeptidyl peptidase-IV (DPP-IV) inhibitors Onglyza (saxagliptin), Galvus (vildagliptin), and...
View ArticleDiabetes: Live Analyst Webchat
Date: Friday 12th July Time: 11am EST /4pm GMT Location: LinkedIn Discussion Group – Datamonitor Healthcare Following a number of developments across key pipeline and marketed diabetes treatments in...
View ArticleDiabetes Analyst Webchat: Q/A Transcript
Following our live Analyst webchat on LinkedIn last week focused on key developments across key pipeline and marketed diabetes treatments, we are happy to share the session highlights with you below...
View ArticleClik here to view.
‘Over half of UK adults are overweight or obese’
Over half of UK adults are overweight or obese, according to leading independent analyst Datamonitor Healthcare. Following a summer of sport and the promise of an Olympic legacy, new research has...
View ArticleClik here to view.
‘American children set for obesity rise while world gets thinner…’
As the rest of the world faces up to its weight problems, the USA is falling behind as a growing number of American children are set to become overweight or obese. Independent analyst Datamonitor...
View ArticleTop 5 Clinical Setbacks of 2014: Takeda’s fasiglifam
The penultimate clinical study setback included in SCRIP and Datamonitor Healthcare’s top 5 clinical setbacks of 2014, focuses on metabolic. It hasn’t been a bad year all-round for metabolic-focused...
View ArticleFuture Market Dynamics in Type 2 Diabetes
2015 will see the type 2 diabetes market subject to unprecedented change due to the entry of the first basal insulin biosimilars. However, due to the use of more expensive therapies in place of...
View ArticleEvolution of the Biosimilars Landscape
Approval of the US biosimilar approval pathway has coincided with increased Big Pharma activity and a surge in new Phase III clinical trials. 2014 was a standout year for innovator biologic approvals,...
View ArticleADA 2015: TECOS study demonstrates Januvia’s cardiovascular safety
Merck & Co presented data from its large-scale, placebo-controlled trial investigating the cardiovascular (CV) safety of its dipeptidyl peptidase-IV (DPP-IV) inhibitor Januvia (sitagliptin). The...
View ArticleType 2 Diabetes Pipeline from Start to Finish
With new treatment options set to launch in the treatment of type 2 diabetes over the next few years, knowing how they will fair and whether or not that type of treatment will succeed is imperative if...
View Article
